Want to see TECH full AI Analyst Report?
TECH Stock Chart & Stats
$59.23
-$0.13(-0.17%)
At close: 4:00 PM EST
$59.23
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$43.20 - $72.16
Previous CloseN/A
Volume102.39K
Average Volume (3M)3.08M
Market Cap
$9.07B
Enterprise Value$8.69B
Total Cash (Recent Filing)$209.82M
Total Debt (Recent Filing)$290.32M
Price to Earnings (P/E)82.4
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.71
Shares Outstanding156,568,760
10 Day Avg. Volume2,976,153
30 Day Avg. Volume3,079,255
Financial Highlights & Ratios
PEG Ratio-1.95
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue7.18
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda33.69
Forecast
1Y Price Target
$66.09Price Target Upside11.58% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)2.06
Revenue Forecast (FY)$1.26B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Low LeverageOperating cash flow that exceeds operating profit and a high free cash flow conversion (FCF/net income ~0.91) provide durable financial flexibility. Conservative leverage (debt/equity ~0.13) lets the company fund R&D, support instrument-install base economics, pursue M&A or withstand multiquarter biotech funding cycles without liquidity stress.
High Margins And Improving ProfitabilitySustained high gross margins and recent sequential margin expansion indicate strong pricing power and a high‑value product mix (instruments plus consumables). Durable margin structure supports reinvestment, funds commercialization of strategic platforms, and cushions earnings through volume cyclicality common in life‑science spend.
Spatial Biology/COMET Product MomentumRapid COMET growth, a record backlog and China installation show structural adoption in multi‑omics and spatial biology. As a platform with recurring consumables and service needs, COMET growth can create durable, high‑margin annuity revenue and strengthen long‑term competitive positioning in a growing market niche.
Bears Say
Material Trailing Revenue DeclineA ~39% TTM revenue decline represents a material growth reset rather than a transient blip. Loss of scale pressures operating leverage, compresses returns, and makes multi‑quarter recovery contingent on sustained demand rebounds from large pharma, China growth or restored biotech early‑stage spending rather than solely on internal execution.
Lumpy Orders & Early‑stage Biotech WeaknessDependence on large, timing‑sensitive GMP/cell‑therapy orders and volatile early‑stage biotech customers creates persistent revenue lumpiness. These structural timing effects and soft RUO demand reduce predictability of consumable revenues and complicate capacity and inventory planning across quarters.
Profitability Compressed By Mix And VolumeSignificant year‑over‑year margin compression and declining net margins reflect unfavorable product mix and volume deleverage. If mix/volume headwinds persist, this reduces cash available for R&D and go‑to‑market investment, erodes return on invested capital and limits the company's ability to scale new platforms profitably.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $43.20 and its highest was $72.16 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $9.07B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on May 06, 2026. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.534 by -$0.004.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.54%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.52.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,568,760 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.53 in its last earnings report, missing expectations of $0.534. Following the earnings report the stock price went down -16.364%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$66.09 (11.58% Upside)
$66.09 (11.58% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $320.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.99%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$66.09
▲(11.58% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.30% Insiders
45.08% Mutual Funds
1.52% Other Institutional Investors
25.23% Public Companies and
Individual Investors